NHS Greater Glasgow & Clyde has developed a new pathway for patients diagnosed with bipolar disorder. 

This comes after a report by the University of Glasgow raised concerns about patients across being prescribed medicines that could make symptoms worse, not better. 

The study found most patients were being prescribed antidepressants but not lithium, which is the recommended first choice for long-term treatment.  

Treatment guidelines caution that taking antidepressants without a mood stabiliser such as lithium can exacerbate some symptoms of bipolar disorder.  

Dr Michael Smith, lead associate medical director for mental health said: “This report looked at data between 2009 and 2016.  

“Since then we have worked with Professor Smith, the author of the research, to tailor a pathway dedicated to individual patient needs.  

“Improvements to bipolar care are a particular focus of the Mental Health strategy for Greater Glasgow & Clyde and we are at the forefront of care for bipolar patients.”